Performance analysis of Galmed Pharmaceuticals (GLMD)
Annual Return
Over the past 3 years, GLMD has had an average annual return of -76.21%, underperforming the benchmark SPY, which returned +22.77% annual.
Over the past 5 years, GLMD has had an average annual return of -73.76%, underperforming the benchmark SPY, which returned +14.05% annual.
Over the past 10 years, GLMD has had an average annual return of -49.67%, underperforming the benchmark SPY, which returned +15.53% annual.
Since Mar 13, 2014, GLMD has had an average annual return of -48.48%, underperforming the benchmark SPY, which returned +14.17% annual.
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| +0% | -75.00% | -42.86% | -93.98% | -72.56% | -41.46% | -46.20% | -15.38% | -25.35% | +160.66% | -53.87% | +31.21% |
| 2014 | |||||||||||
| -59.47% |
Monthly Return
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Annually Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +0% | -33.33% | +0% | +0% | +50% | +0% | +0% | ||||||
| 2025 | -8.33% | -27.27% | -25.00% | -16.67% | +20% | +16.67% | -14.29% | -16.67% | +0% | +0% | -20.00% | -25.00% | -75.00% |
| 2024 | -19.05% | +5.88% | -11.11% | +0% | +6.25% | -23.53% | +7.69% | -7.14% | +107.69% | -51.85% | -15.38% | +9.09% | -42.86% |
| 2023 | +32.38% | -27.49% | -11.04% | -27.18% | -0.92% | -35.35% | -61.15% | -29.63% | -23.68% | -37.93% | -5.56% | +23.53% | -93.98% |
| 2022 | -11.01% | -11.13% | +10.44% | +4.41% | -69.14% | +26.82% | -22.69% | -7.69% | -33.02% | +22.58% | -23.31% | +71.08% | -72.56% |
| 2021 | +19.01% | +7.27% | -13.59% | -4.96% | -20.24% | +16.90% | -18.08% | +31.32% | -14.66% | -11.49% | +2.03% | -27.77% | -41.46% |
| 2020 | -10.37% | -6.38% | -28.65% | +26.01% | +8.93% | +0.63% | +1.47% | +0.62% | -27.65% | -11.92% | +23.79% | -19.22% | -46.20% |
| 2019 | +15.82% | +4.16% | -0.85% | -4.89% | -22.65% | +22.29% | -17.82% | -13.74% | -8.27% | -12.43% | +7.52% | +28.43% | -15.38% |
| 2018 | +9.07% | -48.70% | +8.78% | +6.65% | +6.24% | +88.57% | +14.12% | -0.22% | +0.22% | -34.10% | -4.24% | -20.30% | -25.35% |
| 2017 | +16.23% | +27.43% | -5.95% | +5.94% | -2.51% | +22.78% | +13.71% | +15.02% | +12.71% | -10.29% | -1.95% | +13.81% | +160.66% |
Drawdown analysis of Galmed Pharmaceuticals (GLMD)
The maximum drawdown for the GLMD was -99.98%, occurring on Feb 4, 2026. This drawdown has not yet recovered.
The current GLMD drawdown is -99.98%.
Since Mar 13, 2014 GLMD has experienced the following drawdowns:
- 50% or more: 2 times
- 40% or more: 2 times
- 30% or more: 2 times
- 20% or more: 2 times
- 10% or more: 2 times
| Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -99.98% | Jun 13, 2018 | 1921 | Feb 4, 2026 | Ongoing | Ongoing | Ongoing |
| -81.30% | Mar 18, 2014 | 665 | Nov 3, 2016 | 402 | Jun 12, 2018 | 1067 |